
In this Q+A interview, Matthew Greenhawt, MD, breaks down a poster presentation from AAAAI / WAO joint congress meeting, highlighting increasing EoE incidence and prevalence.

In this Q+A interview, Matthew Greenhawt, MD, breaks down a poster presentation from AAAAI / WAO joint congress meeting, highlighting increasing EoE incidence and prevalence.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The expanded indication now includes children aged 5 through 11 years, in addition to patients aged 12 to 65 years.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from February 2025.

"The measles outbreak that is currently happening in Texas and New Mexico is occurring in an area of the states that have very high anti-vaccine sentiments," Tan said.

A study finds air lead exposure increases infant mortality, linking emissions to low birthweight, SUID, and respiratory issues, urging stricter regulations.

Metformin does not influence breastfeeding rates in patients with type 2 or early diabetes, according to recent data.

"Vaccines are our absolute best defense for protecting people of all ages against many serious infectious diseases," Tan said in a statement as president of IDSA.

The application is for children aged 2 to 5 years with mild-to-moderate atopic dermatitis.

Find out how you did on the quiz.

In this quiz, we test your knowledge of the AAP's new algorithm and updated recommendations for newborn screening for critical congenital heart disease.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, breaks down key highlights of the latest double issue of Contemporary Pediatrics.

The human, pasteurized human milk fortifier is approved for term infants (> 37 weeks) following corrective surgery for the gastrointestinal disorder gastroschisis.

Updated data from the phase 1/2 CHORD trial in 12 children with profound genetic hearing loss were presented at the Association for Research in Otolaryngology’s 48th Annual MidWinter Meeting.

Nearly 40% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI-75.

On exam, the patient is found to have circular, slightly raised, blanching, erythematous papules on the lower extremities and abdomen.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

“In some cases, that meant that we could actually go after the primary pathology or the primary cause of the condition in a way that we never would have thought of before."

Study findings underscore the effectiveness of a dual approach to RSV prevention.

Can you diagnose this patient in our most recent puzzler poll?

Sanjiv Harpavat, MD, PhD, FAAP, lead author of a clinical report recently released by the AAP on identifying infants with biliary atresia, joined to discuss the report and guidance for primary care.

The FDA has accepted PTC Therapeutics' NDA for vatiquinone, a potential treatment for Friedreich's ataxia, with a decision expected by August 19, 2025.

In a recent study, the rate of infant deaths was increased by 5.6% in US states implementing abortion bans.

0.05% atropine was associated with a higher incidence of mild side effects, though it was more effective in controlling myopia progression compared to 0.01% atropine or placebo.

In this quiz, we test your knowledge of the AAP's new algorithm and updated recommendations for newborn screening for critical congenital heart disease.

Amin Barakat, MD, FAAP, details meningococcal disease vaccines and highlights the recently FDA-approved MenABCWY vaccine from GSK.

90-day interim biopsy data in the first 3 patients revealed an average microdystrophin expression of 110% and improvements in muscle health and resilience biomarkers.

Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN offers her thoughts on the recent FDA approval of GSK's meningococcal ABCWY vaccine.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally.